Pfizer Affirms Patents and throws off Challenge from Teva

The U.S. Court of Appeals of the Federal Circuit (FAFC) reaffirmed two out of three of Pfizer’s patents for the arthritis pain drug Celebrex on Friday. Teva will now have to wait until May 2014 to market their generic version of the drug.

Celebrex has shown clear benefits for arthritis sufferers but has also been alleged to risk heart attacks and strokes.



Categories: drugs, Intellectual Property, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: